Technologically Processed Highly Diluted Antibodies to S100 Protein in the Treatment of Neurotic Disorders: The Review

Khacheva, Kristina K.; Khakimova, G. R.; Glazunov, Alexey Borisovich; Fateeva, V V

doi:10.5772/intechopen.92207

Cited by 3 publications

(3 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HD Abs to S100 have been comprehensively studied in pre-clinical studies where their stress-protective, anxiolytic, antidepressant, antiamnestic and neuroprotective activities have been demonstrated 30 . Clinical trials (CTs) have shown the efficacy and safety of HD Abs to S100 in patients with anxiety NDs as well as in patients with anxiety and concurrent neurological diseases 30 . Moreover, the effectiveness of HD Abs in patients with anxiety disorders was comparable to that of benzodiazepines 30 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

Парфенов

Камчатнов

Хасанова

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The existing treatments for somatoform dysfunction (SfD), reaction to severe stress (RSS), and adjustment disorders (AjD) are insufficiently effective and safe. Anxiolytic drug Tenoten proved effective in clinical trials (CT). The aim of this multicenter double-blind placebo-controlled randomized CT was to investigate the safety and efficacy of Tenoten in the treatment of anxiety in adults with SfD, RSS, AjD and other neurotic disorders (oNDs). 390 adult patients with SfD, RSS and AjD or oNDs with the Hospital Anxiety and Depression scale-anxiety (HADS-A) score ≥ 11 were randomized into 4 groups (n = 127 in Tenoten group 1 (4 tablets/day); n = 131 in Tenoten group 3 (8 tablets/day), n = 132 in combined Placebo group 2 + 4). The changes from baseline in the mean Hamilton Anxiety Rating Scale (HAM-A) score in groups 1 and 3 after 12 weeks were the primary outcome. The decrease of the HAM-A score from 18.81 ± 5.81 to 7.26 ± 4.63 (in group 1) and from 18.38 ± 4.3 to 6.40 ± 4.02 (in group 3) was observed post-treatment (pgroup 1/placebo = 0.0055, pgroup 3/placebo < 0.0001). Overall, 46 adverse events (28 in the Tenoten groups and 18 in the Placebo) were reported without any difference between the study groups. Tenoten performed significantly more effective than placebo in the anxiety treatment of adults with SfD, RSS, AjD and oNDs (clinicaltrials.gov NCT03036293).

show abstract

Section: Introductionmentioning

confidence: 99%

“…Clinical trials (CTs) have shown the efficacy and safety of HD Abs to S100 in patients with anxiety NDs as well as in patients with anxiety and concurrent neurological diseases 30 . Moreover, the effectiveness of HD Abs in patients with anxiety disorders was comparable to that of benzodiazepines 30 .…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

Парфенов

Камчатнов

Хасанова

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Though Tenoten is not registered in USA, FDA experts concluded that drugs based on HD Abs should be studied and proceeded for registration using a standard regulatory approach [29]. Clinical trials (CTs) have demonstrated the efficacy and safety of HD Abs to S100 in patients with anxiety [30].…”

Section: Introductionmentioning

confidence: 99%

The Treatment of Anxiety in Patients with Somatoform Dysfunction, Reaction to Severe Stress and other Neurotic Disorders: A Multicenter Double-blind Placebo-controlled Randomized Trial

Парфенов

Камчатнов

Амелин

et al. 2021

Preprint

View full text Add to dashboard Cite

The existing treatment of somatoform dysfunction (SD), reaction to severe stress (RSS) and adjustment disorders (AjD) is insufficiently effective and safe. Anxiolytic drug Tenoten (Materia Medica Holding) is shown to be effective in clinical trials (CT). Objectives The aim of multicenter double-blind placebo-controlled randomized CT was to investigate the safety and efficacy of Tenoten in the anxiety treatment of adults with SD, RSS, AjD and other neurotic disorders (oNDs). Methods 390 adults with SD, RSS and AjD or oNDs with the Hospital Anxiety and Depression scale-anxiety (HADS-A) score≥11 were randomized into 4 groups (Tenoten group 14 tablets/day n=127; Tenoten group 3 8 tablets/day n=131, combined Placebo group 2+4 n= 132). The changes from baseline in the mean Hamilton Anxiety Rating Scale (HAM-A) score in groups 1 and 3 after 12 weeks was the primary outcome. Results The decrease in the HAM-A score from 18.81±5.81 to 7.26±4.63 (group 1) and from 18.38±4.3 to 6.40±4.02 (group 3) was observed post-treatment (p group 1/placebo =0.0055, p group 3/placebo <0.0001). The mean changes in the scores in the groups 1, 3 and the Placebo were 11.25, 11.91 and 9.71, respectively. In total, 46 AEs (28 AEs in the Tenoten groups, 18 in the Placebo) were registered in 37 patients (20 in the Tenoten groups, and 17 in the Placebo). No differences in frequency of AEs between groups were found. Conclusions Tenoten was shown to be significantly more effective than placebo in the anxiety treatment of adults with SD, RSS, AjD and oNDs (clinicaltrials.gov NCT03036293).

show abstract

Neurodevelopmental Disorders in Children: Neuroplasticity and Possibilities of Nootropic Pharmacotherapy

Zavadenko

2023

Nejrohimiâ

View full text Add to dashboard Cite

Neurodevelopmental Disorders (NDD) are characterized by disturbances of the formation of cognitive functions, communication skills, behavior characteristics and / or motor skills, which are caused by abnormalities in the course of the processes of neuroontogenesis. Factors of the etiology and pathogenesis of NDD include genetic mechanisms, early damage to the developing brain, and adverse external influences. Most forms of NDD manifest themselves in the early stages of development and before the child begins school eduction. The most common NDD, with which medical doctors of various specialties constantly meet, include speech development disorders and attention deficit hyperactivity disorder (ADHD). Since disorders of neuroplasticity processes are considered among the mechanisms of the NDD pathogenesis, their therapy should be aimed at restoring and stimulating the neuroplasticity potential. Manifestations of NDD, undergoing age-related evolution, significantly disrupt normal life and have an adverse effect on various functional areas not only in children, but also in adolescents and adults. The increase in symptoms in patients with NDD at one age or another is not due to the progressive nature of cerebral changes, but to increased difficulties of adaptation with increasing loads, including educational, social, professional ones. Therefore, in most cases, they require many years of complex management and the use of pharmacotherapy, the prospects of which are primarily associated with nootropic drugs. The data of new studies on the effectiveness of nootropics in developmental dysphasia and ADHD are discussed, and possible mechanisms of the nootropics influence on neuroplasticity processes are considered.

show abstract

Technologically Processed Highly Diluted Antibodies to S100 Protein in the Treatment of Neurotic Disorders: The Review

Cited by 3 publications

References 69 publications

RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders

The Treatment of Anxiety in Patients with Somatoform Dysfunction, Reaction to Severe Stress and other Neurotic Disorders: A Multicenter Double-blind Placebo-controlled Randomized Trial

Neurodevelopmental Disorders in Children: Neuroplasticity and Possibilities of Nootropic Pharmacotherapy

Contact Info

Product

Resources

About